US Patent

US7199162 — Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation

Method of Use · Assigned to Medac Gesellschaft fuer Klinische Spezialpraeparate mbH · Expires 2026-10-12 · 0y remaining

Vulnerability score 93/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of treosulfan as a conditioning agent before bone marrow or blood stem cell transplantation.

USPTO Abstract

The invention relates to the use of treosulfan as a conditioning agent before allogenic transplantation of bone marrow or haematopoietic stem cells, whereby treosulfan is administered, either as single effective agent, or in combination with other chemotherapetic agents or immunosuppressant agents.

Drugs covered by this patent

Trecondi (TREOSULFAN) · Medexus

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4142`	—	Trecondi
`U-4142`	—	Trecondi

Patent Metadata

Patent number: US7199162
Jurisdiction: US
Classification: Method of Use
Expires: 2026-10-12
Drug substance claim: No
Drug product claim: No
Assignee: Medac Gesellschaft fuer Klinische Spezialpraeparate mbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.